Editorial review
Educational content is reviewed for source quality, clinical boundaries, and readability. It is not medical advice; confirm care decisions with a licensed clinician.
What the Spravato REMS Program Requires
The Spravato Risk Evaluation and Mitigation Strategy (REMS) requires every dose of esketamine nasal spray to be given in a certified healthcare setting, self-administered by the patient under a health care provider's direct observation, and followed by at least two hours of on-site monitoring for sedation, dissociation, and changes in blood pressure. The U.S. Food and Drug Administration (FDA), the federal agency responsible for approving and regulating prescription drugs, required this program when it approved Spravato (esketamine) in March 2019 for treatment-resistant depression (TRD) because the drug carries risks of sedation, dissociation, and misuse that the agency determined require direct clinical supervision rather than take-home dosing.
A REMS is an FDA-mandated safety program that restricts how a high-risk drug can be prescribed, dispensed, or administered so that its benefits continue to outweigh its risks. Esketamine is also a Schedule III controlled substance under the Controlled Substances Act, which adds separate prescribing and record-keeping rules on top of the REMS itself. According to the FDA's 2019 approval announcement, Spravato is available only through a restricted distribution system, and patients cannot take the medication home.
Quick Answer
The Spravato REMS requires patients to receive every dose at an FDA-certified healthcare setting, self-administer the nasal spray under a clinician's direct observation, and stay for at least two hours of monitoring afterward. Certified pharmacies can only ship Spravato to certified sites, never directly to patients. The program exists because esketamine can cause sedation, dissociation, and elevated blood pressure shortly after dosing, and it does not apply to ketamine prescribed off-label, which has no federal REMS requirement.
Why Esketamine Has a REMS and Off-Label Ketamine Doesn't
Spravato carries a REMS because it went through FDA drug approval, and the FDA can attach a REMS to any approved drug when it identifies a serious risk that needs active management. Generic ketamine, by contrast, is FDA-approved only as a general anesthetic; when it's used for depression, pain, or other mental health conditions, that use is off-label, meaning a licensed prescriber is using an approved drug for a purpose the FDA hasn't formally reviewed for that indication. Off-label ketamine has no federal REMS, so monitoring protocols, dosing intervals, and site requirements vary by clinic rather than being set by a single FDA-mandated program. You can read more about how that legal distinction plays out in practice in our guide to whether ketamine is legal and in the complete guide to ketamine.
This difference matters for comparing options. Esketamine's REMS structure gives patients a standardized, federally enforced safety floor at every certified site. Off-label ketamine's flexibility means protocols can differ meaningfully between an infusion clinic and a psychiatric practice, so it's worth asking any provider directly how they monitor patients during and after dosing.
Compare evidence and options
Compare ketamine with other treatment paths using neutral explainers.
Compare optionsThe Three Core Requirements of the Spravato REMS
The FDA-approved REMS is built around three linked requirements that apply to every certified site nationwide.
- Certified healthcare setting: Spravato can only be administered in a medical office, clinic, or hospital outpatient setting that has enrolled in the REMS program, agreed to its monitoring protocols, and been certified to receive shipments of the drug.
- Direct observation of self-administration: the patient administers the nasal spray themselves, but a health care provider must be physically present to observe the dose and respond if a problem occurs.
- Restricted pharmacy distribution: only certified pharmacies can dispense Spravato, and they may only ship it to certified healthcare settings, never to a patient's home or a standard retail pharmacy counter.
These requirements work together: a patient cannot obtain the drug outside a certified site, cannot dose without supervision, and cannot leave before the monitoring window closes.
What a Spravato-Certified Site Must Have in Place
- Enrollment in the Spravato REMS with a certified pharmacy relationship for drug supply
- Staff trained on dosing observation, dissociation screening, and blood pressure monitoring
- A designated space where the patient can be monitored for at least two hours post-dose
- Equipment and protocols to manage sedation or a blood pressure spike if one occurs
- A discharge process confirming the patient is stable and has arranged transportation home
How a Spravato Dosing Visit Unfolds Under the REMS
Pre-dose check
The provider records baseline blood pressure and reviews the patient's current mental status before dosing begins.
Supervised self-administration
The patient sprays the esketamine dose themselves while the provider observes directly, as the REMS requires.
Two-hour monitoring window
Blood pressure is typically rechecked around 40 minutes post-dose, with the provider watching for sedation, dissociation, or other reactions throughout the required two hours.
Discharge assessment
Before the patient leaves, the provider confirms blood pressure has returned to a safe range, dissociative effects have eased, and the patient is not driving themselves home.
Driving Restriction Applies the Entire Day of Treatment
The Spravato REMS requires patients not to drive, operate heavy machinery, or make important decisions on the day of each treatment, and to wait until after a full night of restful sleep before doing so. Clinics require patients to arrange a ride home in advance, since a self-driven departure isn't permitted under the program.
Patient Enrollment and the REMS Agreement
Before a first dose, patients review and sign a REMS enrollment form acknowledging the drug's risks, including sedation, dissociation, elevated blood pressure, and the potential for misuse given esketamine's Schedule III status. This documentation sits alongside informed consent for treatment and is separate from insurance authorization. Because Spravato is approved specifically for treatment-resistant depression and, since August 2020, for depressive symptoms in adults with major depressive disorder who have suicidal ideation or behavior, the REMS also ties into how eligibility is documented for each indication.
Dosing frequency under REMS-supervised treatment typically starts at twice weekly for the first month, then tapers based on clinical response, which means REMS monitoring isn't a one-time event but a recurring visit structure for as long as the patient continues treatment. For background on how esketamine's clinical evidence compares with other delivery routes, see our coverage of IV ketamine versus nasal esketamine research.
Spravato REMS Key Figures
REMS Oversight Advantages
- Standardized safety protocol enforced at every certified site nationwide
- Clinical staff present to manage sedation or blood pressure changes in real time
- No take-home dosing, which limits diversion risk given esketamine's controlled substance status
Considerations
- Each dose requires an in-person visit lasting roughly two to two-and-a-half hours
- Patients must arrange transportation home for every appointment
- Access depends on living near a certified site, which can be limited in rural areas
What This Means for Cost, Access, and Comparing Options
REMS monitoring adds clinic time and staffing that factor into how esketamine treatment is billed, separate from the drug cost itself. Because monitoring is federally required rather than clinic-optional, patients evaluating Spravato should expect the same core visit structure, observation, and two-hour wait regardless of which certified provider they choose. That consistency is a tradeoff: it standardizes safety, but it also means the visit length and supervision requirements aren't something a provider can shorten. For general safety expectations across ketamine treatment, including side effects that monitoring is designed to catch, see our overview of understanding ketamine safety and safety and side effects.
This article is educational and does not substitute for medical advice. Whether Spravato, off-label ketamine, or another route fits your situation depends on your diagnosis, treatment history, and access to a certified or supervising provider, so discuss your options with a licensed clinician.
Compare Ketamine Delivery Methods
See how esketamine's REMS-supervised nasal route stacks up against IV, IM, and sublingual ketamine on evidence, monitoring, and access.
Frequently Asked Questions
No. The REMS is specific to Spravato (esketamine) because it's the drug that received FDA approval with that restriction attached. Off-label ketamine, used by IV, IM, sublingual, or other routes, has no federal REMS, though individual clinics set their own monitoring protocols.
No. The REMS requires patients not to drive on the day of treatment and to wait until after a restful night's sleep. You need to arrange a ride in advance of every dosing visit.
Plan for roughly two to two-and-a-half hours per visit: a brief pre-dose check, the observed self-administration, and the required two-hour monitoring window before discharge.
The FDA sets the REMS requirements, and certified pharmacies and healthcare sites agree to follow them as a condition of being able to order and administer the drug. Sites that don't maintain compliance risk losing their certification to dispense Spravato.
Coverage varies by plan. The monitoring visit is typically billed as part of the treatment encounter alongside the drug cost, so it's worth confirming with your insurer and the clinic how the visit is coded before starting treatment.
Share
Related Reading
Contact Ketamine Resource
Send corrections, partnership questions, or advertising inquiries.